Population pharmacokinetic‐pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study

• मुख्य लेखकों: Yun Seob Jung (लेखक), Byung Hak Jin (लेखक), Min Soo Park (लेखक), Choon Ok Kim (लेखक), Dongwoo Chae (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Wiley, 2024-01-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Clopidogrel is an antiplatelet drug used to reduce the risk of acute coronary syndrome and stroke. It is converted by CYP2C19 to its active metabolite; therefore, poor metabolizers (PMs) of CYP2C19 exhibit diminished antiplatelet effects. Herein, we conducted a proof‐of‐concept study for us...